A Phase I Dose Escalation Study Evaluating MK1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors.

Trial Profile

A Phase I Dose Escalation Study Evaluating MK1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2016

At a glance

  • Drugs AZD-1775 (Primary) ; Carboplatin; Cisplatin; Gemcitabine
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 06 Sep 2016 Results assessing safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of AZD1775 published in the Journal of Clinical Oncology.
    • 29 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 31 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top